Form POS AM - Post-Effective amendments for registration statement:
SEC Accession No. 0001104659-26-037725
Filing Date
2026-03-31
Accepted
2026-03-31 16:09:30
Documents
71

Document Format Files

Seq Description Document Type Size
1 POS AM sngx-20251231xposam.htm   iXBRL POS AM 2726984
2 EX-21 sngx-20251231xex21.htm EX-21 13848
3 EX-23 sngx-20251231xex23.htm EX-23 4955
4 GRAPHIC sngx-20251231xposam001.jpg GRAPHIC 6870
5 GRAPHIC sngx-20251231xposam007.jpg GRAPHIC 784
6 GRAPHIC sngx-20251231xposam008.jpg GRAPHIC 796
7 GRAPHIC sngx-20251231xposam022.jpg GRAPHIC 3974
  Complete submission text file 0001104659-26-037725.txt   9022924

Data Files

Seq Description Document Type Size
8 EX-101.SCH sngx-20251231.xsd EX-101.SCH 55573
9 EX-101.CAL sngx-20251231_cal.xml EX-101.CAL 55439
10 EX-101.DEF sngx-20251231_def.xml EX-101.DEF 236937
11 EX-101.LAB sngx-20251231_lab.xml EX-101.LAB 483513
12 EX-101.PRE sngx-20251231_pre.xml EX-101.PRE 363978
75 EXTRACTED XBRL INSTANCE DOCUMENT sngx-20251231xposam_htm.xml XML 1488993
Mailing Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540
Business Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540 609-538-8200
SOLIGENIX, INC. (Filer) CIK: 0000812796 (see all company filings)

EIN.: 411505029 | State of Incorp.: DE | Fiscal Year End: 1231
Type: POS AM | Act: 33 | File No.: 333-276511 | Film No.: 26821797
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)